Spondyloarthritis & psoriatic arthritis
Differences in treatment response between female and male psoriatic arthritis patients during IL-12/23 therapy with or without methotrexate: post hoc analysis of results from the randomised MUST trial
Authors' conclusion
Females and males with PsA had differences in baseline characteristics, treatment responses and adverse events during therapy.
Study context
- Population
- Patients with active PsA initiating open-label ustekinumab
- Participants
- 166 patients
- Comparison
- Females vs males with PsA on open-label ustekinumab, randomised to methotrexate (MTX) or placebo
- Ustekinumab+MTX, femalen = 37
- Ustekinumab+MTX, malen = 50
- Ustekinumab+placebo, femalen = 32
- Ustekinumab+placebo, malen = 47reference
Methodological detailsexploratory, sex-stratified, investigator-initiated, multicentre, phase 3b
- Exploratory
- Sex-stratified
- Investigator-initiated
- Multicentre
- Phase 3b
Primary result
As reported in the abstract
Treatment response by sex · week 24
- Both females and males showed marked improvements to ustekinumab with or without MTX
- Females generally had numerically reduced treatment responses vs males; differences not statistically significant
Further findings
Baseline characteristics by sex
- Females had significantly longer time since PsA diagnosis and greater impairment in physical function, but similar joint counts
Effect of MTX
- No overall effect of MTX on treatment outcomes; associated with faster enthesitis responses in males only
Safety
Adverse events
- Generally comparable; females on ustekinumab+MTX had higher levels of gastrointestinal disorders
Original publication
Differences in treatment response between female and male psoriatic arthritis patients during IL-12/23 therapy with or without methotrexate: post hoc analysis of results from the randomised MUST trial. RMD Open. Published 19 December 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →